middle.news
OncoSil Medical Doubles Dose Sales Amid Promising Pancreatic Cancer Trial Data
9:44am on Tuesday 24th of February, 2026 AEDT
•
Healthcare
Read Story
OncoSil Medical Doubles Dose Sales Amid Promising Pancreatic Cancer Trial Data
9:44am on Tuesday 24th of February, 2026 AEDT
Key Points
100% increase in OncoSil™ dose sales in 1H FY26
Positive preliminary PANCOSIL Phase 1-2 study results with strong safety profile
First commercial OncoSil™ treatments in Germany, UK, Portugal, and Türkiye
Completion of TRIPP-FFX trial last patient last visit, with results expected in 1H CY26
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
ONCOSIL MEDICAL (ASX:OSL)
OPEN ARTICLE